XML 244 R200.htm IDEA: XBRL DOCUMENT v3.22.4
Other operating expenses - Other Income and Expense (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses € 2,531 € 1,805 € 1,415 [1]
Other operating income 1,969 859 697 [1]
Other operating income/(expenses), net related to the Regeneron Alliance (1,231) (1,373) (926)
Antibodies collaboration agreement | Regeneron Pharmaceuticals, INC      
Disclosure Of Other Operating Income Expenses [Line Items]      
Commitments received for development costs 2,700 2,900  
Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses 2,378 1,568 1,090
Other operating income (expense) | Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 1,147 195 164
Monoclonal Antibody Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses 2,367 1,429 1,001
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses 2,325 1,253 727
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 434 127 75
Monoclonal Antibody Alliance | Commercialization related expenses      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses 476 303 349
Immuno-Oncology Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 16 68 89
Others      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income and expenses € 1,120 € (12) € (14)
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.